Cero Therapeutics Holdings, Inc. 8-K Report: Key Insights & Stock Details

Here are the key insights extracted from the provided financial report section regarding Cero Therapeutics Holdings, Inc.:

1. Entity Information:

• Company Name: Cero Therapeutics Holdings, Inc.
• CIK Number: 0001870404
• Location: 201 Haskins Way, Suite 230, South San Francisco, CA 94080
• Contact Number: 650-407-2376

2. Filing Information:

• Form Type: 8-K
• Filing Date: January 7, 2025
• SEC File Number: 001-40877
• IRS Employer Identification Number (EIN): 87-1088814

3. Stock Information:

• Common Stock: Par value of $0.0001 per share.
• Warrants: Each whole warrant is exercisable for one share of common stock.
• Ticker Symbols:
• • Common Stock: CERO (NASDAQ)
  • Warrants: CEROW (NASDAQ)

4. Context and Period:

• The report covers a specific context identified as "AsOf2025-01-07", indicating that the information is relevant as of January 7, 2025.

5. Units of Measure:

• Financial figures are presented in US dollars (USD) and shares.

6. Dimensions:

• The report references specific dimensions under US GAAP related to stock classes, indicating that it includes data for both common stock and warrants.

Insights:

• The filing is part of a regulatory requirement (Form 8-K) likely indicating a significant event or changes impacting the company as of the date mentioned.
• The presence of warrants suggests potential future dilution of shares, as these securities can be converted into common stock, impacting existing shareholders.
• The low par value of the common stock ($0.0001) reflects a structure that is common in biotech or high-growth companies, allowing for flexibility in capital raises.
• The information is critical for investors, analysts, and stakeholders looking to assess the company's capital structure and potential for future equity issuance or dilution.

This analysis helps in understanding the financial positioning and potential future developments of Cero Therapeutics Holdings, Inc.